Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis—a comprehensive review

Baricitinib is an oral selective inhibitor of Janus kinase (JAK)1 and JAK2 that has proved effective and well tolerated in the treatment of rheumatoid arthritis (RA) in an extensive programme of clinical studies of patients with moderate-to-severe disease. In a phase 2b dose-ranging study of baricit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Res Ther
Main Authors: Emery, Paul, Durez, Patrick, Hueber, Axel J., de la Torre, Inmaculada, Larsson, Esbjörn, Holzkämper, Thorsten, Tanaka, Yoshiya
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7784289/
https://ncbi.nlm.nih.gov/pubmed/33397481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13075-020-02379-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados